About_

A Team That Pushes Boundaries

To fully integrate cancer research and care, xCures assembled an experienced, boundary-pushing team with the expertise, creativity, and persistence needed to solve the biggest problems in oncology. We have created and piloted a fully functioning beta solution in brain and pancreatic cancer, and signed commercial contracts and generated interest from key strategic partners across the world of technology-driven healthcare.

Founders

Marty Tenenbaum, Ph.D

Co-Founder and Chairman

Marty Tenenbaum is a renowned computer scientist, Internet entrepreneur and cancer survivor. He founded Cancer Commons and CollabRx (NASD: CRLX) to help each cancer patient obtain the best possible outcome. He is an Internet commerce pioneer and visionary, having founded EIT (1990) and CommerceNet (1994) to accelerate business use of the Internet, and later, was an officer and director of Commerce One, Webify Solutions (sold to IBM in 2006),  and Medstory (sold to Microsoft in 2007).

Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, a former Director of the Public Library of Science (PLoS) and Patients Like Me, and a former consulting professor of Computer Science at Stanford. He currently serves as a Director of CommerceNet and Efficient Finance.  Dr. Tenenbaum holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a Ph.D. from Stanford, and has received numerous awards for his work in AI and as a patient advocate.

Jeff Shrager, Ph.D

Co-Founder & Director of Research

Jeff Shrager, PhD, has over 20 years of experience in applying high performance cloud computing and machine learning in biological science. After an AI/machine learning PhD at CMU, Dr. Shrager worked for a decade at Xerox PARC. Following that, he co-founded a successful computational drug discovery company, and then spent a decade doing wet lab biology, and developing a cloud-based platform for intelligent molecular biocomputing. In the last decade, Jeff co-founded another genomic startup, and then joined SRI International’s biological AI-group and Cancer Commons. As an xCures co-founder, Jeff is responsible for envisioning and developing both the high level and low level AI and machine learning aspects of the virtual trial and virtual tumor board products.

Management

MIka Newton

Chief Executive Officer

Mika Newton has over twenty years of leadership experience in the life sciences. Most recently he was the Chief Commercial Officer of Doctor Evidence, LLC. Prior to Doctor Evidence he was the General Manager of Clinical Development Services at diaDexus, SVP of Client and Market Development at Evidera, VP of Sales and Marketing at Archimedes, and held sales management and sales operations roles at Quintiles, Invitrogen and Tripos.

William Hoos, MS, MBA

Chief Commercial Officer

William Hoos is a life science executive and investor. Most recently he has worked with drug and diagnostic companies in oncology including as CEO of NQ Oncology and as a consultant to OncoPlex Diagnostics. His work also includes nonprofits including Pancreatic Cancer Action Network and as founder of ClinWiki.

Glenn Kramer, Ph.D.

Chief Technology Officer

Glenn Kramer has delivered products in a wide variety of domains, including AI-enhanced computational geometry engines, transaction processing systems, business intelligence / market monitoring systems, and innovative investment products that use predictive analytics. He holds 22 issued US Patents. He was most recently Chief Data Scientist at SRS Acquiom, where he developed financial and data products for the M&A market. 

Mark Shapiro, MBA, Ph.D.

Vice President CLinical Development

Mark Shapiro is a pharmacologist and widely recognized expert on growth and innovation strategies in clinical research and clinical development. As a management consultant at Campbell Alliance, he led strategic planning, growth, and change management initiatives at many pharmaceutical, biotech and clinical research organizations. He was most recently the SVP, Operations at Clinipace, a global, oncology-focused CRO, where he was part of the leadership team that grew the organization from ten to over a thousand employees worldwide.

John Eckardt, MD

Chief Medical Officer Consulting

Dr. Eckardt brings over twenty years of experience in medical oncology including clinical research, patient care, and education. Prior to joining DAVA Oncology, Dr. Eckardt  worked as a medical oncologist and director of the clinical research program for The Center for Cancer Care and Research in St. Louis, Missouri.  Dr. Eckardt trained in medical oncology at the University of Texas Health Science Center in San Antonio.  He mentored under Dr. Dan Von Hoff in drug development staying on as a clinical instructor at UTHSCSA Cancer Therapy and Research Center.  Dr. Eckardt received a medical degree from Saint Louis University, and did his internal medicine training at St. John’s Mercy Medical Center in St. Louis Missouri.

 

Board of Directors

Marty Tenenbaum, Ph.D.

Chairman

Marty Tenenbaum is a renowned computer scientist, Internet entrepreneur and cancer survivor. He founded Cancer Commons and CollabRx (NASD: CRLX) to help each cancer patient obtain the best possible outcome. He is an Internet commerce pioneer and visionary, having founded EIT (1990) and CommerceNet (1994) to accelerate business use of the Internet, and later, was an officer and director of Commerce One, Webify Solutions (sold to IBM in 2006),  and Medstory (sold to Microsoft in 2007).

Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, a former Director of the Public Library of Science (PLoS) and Patients Like Me, and a former consulting professor of Computer Science at Stanford. He currently serves as a Director of CommerceNet and Efficient Finance.  Dr. Tenenbaum holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a Ph.D. from Stanford, and has received numerous awards for his work in AI and as a patient advocate.

Moe Kermani, Ph.D.

Moe Kermani is a Managing Partner of Vanedge Capital where he focuses on investments in  Cloud computing, Artificial Intelligence, Cybersecurity, Analytics, and Quantum Information.  Prior to that he was President and CEO of Bycast Inc., a world leader in object storage that was successfully acquired by NetApp. Moe has extensive experience working with entrepreneurial companies and taking to market leading-edge technology products.   He holds Ph.D. in physics from the University of British Columbia.



George Hoyem

Mr. Hoyem has more than 25 years of entrepreneurial, operations, and venture capital investing experience in high technology companies. At IQT, the strategic venture capital arm of the Intelligence Community, Hoyem is the Managing Partner for the IQT, West Coast Investment team and heads up the Enterprise IT investment practice area. Hoyem has led dozens of investments at IQT across these investment areas. He has also backed, supported, and served on the boards of several dozen emerging technology companies over his career. Mr Hoyem also serves on the Board of Directors of the National Venture Capital Association, the venture capital community’s flagship trade association where he advocates for issues relevant to corporate and strategic investors.

 

Laurence J. Marton, MD

Dr. Marton serves on the Board of Trustees of the American Association for Cancer Research Foundation and on the Board of Directors of Cancer Commons and the Bay Area American Committee for the Weizmann Institute of Science.  In the for-profit sector, he serves on the Board of Directors of Cellsonics, Dategra, Matternet, Microsonic Systems, Pathologica, RenovoRx, and TOMA Biosciences; is Chair of the Scientific Advisory Board of PharmaJet; is an advisor to Ciitizen and the Precision Medicine World Conference; and is on the Editorial Board of the Journal of Precision Medicine. Previously, Dr. Marton was Dean of the University of Wisconsin Medical School and Chaired the Department of Laboratory Medicine at UCSF.

MIka Newton

Chief Executive Officer

Mika Newton has over twenty years of leadership experience in the life sciences. Most recently he was the Chief Commercial Officer of Doctor Evidence, LLC. Prior to Doctor Evidence he was the General Manager of Clinical Development Services at diaDexus, SVP of Client and Market Development at Evidera, VP of Sales and Marketing at Archimedes, and held sales management and sales operations roles at Quintiles, Invitrogen and Tripos.

Scientific Advisory Board

Keith Flaherty, MD

Chairman

Keith Flaherty is a Professor of Medicine at Harvard Medical School and Director of Clinical Research at the Massachusetts General Hospital Cancer Center, where he was named as the Richard Saltonstall Endowed Chair in Oncology.

 

Jennifer R. Grandis, MD, FACS

Jennifer R. Grandis is the Robert K. Werbe Distinguished Professor in the Department of Otolaryngology for Head and Neck Surgery at the University of California, San Francisco. Dr. Grandis’s research focuses on signal transduction in head and neck squamous cell carcinoma (HNSCC) development and progression. She is an American Cancer Society Clinical Research Professor.

Patricia LoRusso, DO

Patricia LoRusso brings more than 25 years of expertise in medical oncology, drug development, and early phase clinical trials to her position as Professor of Medicine (Medical Oncology) and Associate Cancer Center Director of Experimental Therapeutics, Yale Cancer Center.

Advisory Board

David Hartford

David Hartford has more than 40 years of experience in the U.S. and Europe as a private equity investor, venture capitalist, and entrepreneur. During his career, he has also undertaken direct C-suite roles and been a practicing securities attorney. He was a founding partner of Calibrium AG (formerly known as Aeris Capital) and now is a senior advisor to the firm.

Elizabeth Hutt Pollard

Elizabeth Hutt Pollard is currently the Executive Chair of Applied Silver, Inc. a privately held company addressing infection prevention in the health, athletic and consumer markets. She is a C-Suite veteran and has extensive experience bringing to market highly specialized technology and solutions for healthcare. She currently serves as a strategic advisor to several early-stage life science companies and holds leadership positions in YPO, the premier leadership organization of chief executives in the world.

 

Craig Lipset

Craig Lipset is a recognized leader at the forefront of innovation in clinical research and medicine development. The past Head of Clinical Innovation and Venture Partner at Pfizer, he is currently an advisor to technology and biopharmaceutical companies, leading universities, and the venture community, bringing vision and driving action at the intersection of research, digital solutions, and patient engagement.

Rob Rodin

Rob Rodin is the Chairman and CEO of RDN Group and a strategic investor/advisor and manager, focusing on portfolio companies for several venture capital and private equity funds. He served for more than 10 years as CEO and President of Marshall Industries where he engineered the reinvention of the company, turning a conventionally successful $500 million distributor into a web-enabled $2 billion global competitor.

Josh Tenenbaum, PhD

Josh Tenenbaum is a professor of Computational and Cognitive Science at the Massachusetts Institute of Technology. His research focus at the Computational Cognitive Science group is to understand that most elusive aspect of human intelligence: our ability to learn so much about the world, so rapidly and flexibly. While the group’s core focus is on human learning and reasoning, they also work actively in machine learning and artificial intelligence.